TORNTPHARM.NS Balance Sheet
Torrent Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 00:34
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹2,772.00 Cr. | ₹3,297.00 Cr. | ₹3,455.00 Cr. | ₹4,909.00 Cr. | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹688.00 Cr. | ₹281.00 Cr. | ₹367.00 Cr. | ₹457.00 Cr. | CapitalWorkInProgress |
| Goodwill | ₹338.00 Cr. | ₹338.00 Cr. | ₹339.00 Cr. | ₹3,990.00 Cr. | Goodwill |
| Other Intangible Assets | ₹5,012.00 Cr. | ₹4,503.00 Cr. | ₹4,152.00 Cr. | ₹24,280.00 Cr. | OtherIntangibleAssets |
| Non-current Investments | ₹43.00 Cr. | ₹32.00 Cr. | ₹44.00 Cr. | ₹83.00 Cr. | NoncurrentInvestments |
| Other Non-current Assets | ₹158.00 Cr. | ₹324.00 Cr. | ₹268.00 Cr. | ₹258.00 Cr. | OtherNoncurrentAssets |
| Total Non-current Assets | ₹9,683.00 Cr. | ₹9,450.00 Cr. | ₹9,367.00 Cr. | ₹34,919.00 Cr. | NoncurrentAssets |
| Inventories | ₹2,230.00 Cr. | ₹2,279.00 Cr. | ₹2,541.00 Cr. | ₹3,138.00 Cr. | Inventories |
| Trade Receivables | ₹1,944.00 Cr. | ₹1,844.00 Cr. | ₹1,867.00 Cr. | ₹3,031.00 Cr. | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹508.00 Cr. | ₹835.00 Cr. | ₹573.00 Cr. | ₹1,117.00 Cr. | CashAndCashEquivalents |
| Current Investments | ₹156.00 Cr. | ₹141.00 Cr. | ₹112.00 Cr. | ₹866.00 Cr. | CurrentInvestments |
| Other Current Assets | ₹303.00 Cr. | ₹304.00 Cr. | ₹336.00 Cr. | ₹629.00 Cr. | OtherCurrentAssets |
| Total Current Assets | ₹5,314.00 Cr. | ₹5,611.00 Cr. | ₹5,623.00 Cr. | ₹9,392.00 Cr. | CurrentAssets |
| Total Assets | ₹15,012.00 Cr. | ₹15,061.00 Cr. | ₹14,990.00 Cr. | ₹44,312.00 Cr. | Assets |
| Equity Share Capital | ₹169.00 Cr. | ₹169.00 Cr. | ₹169.00 Cr. | ₹169.00 Cr. | EquityShareCapital |
| Other Equity | ₹6,029.00 Cr. | ₹6,687.00 Cr. | ₹7,422.00 Cr. | ₹8,220.00 Cr. | OtherEquity |
| Equity Attributable to Owners | ₹6,198.00 Cr. | ₹6,856.00 Cr. | ₹7,591.00 Cr. | ₹8,389.00 Cr. | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹0.00 Cr. | N/A | ₹0.00 Cr. | ₹9,196.00 Cr. | NonControllingInterest |
| Total Equity | ₹6,198.00 Cr. | ₹6,856.00 Cr. | ₹7,591.00 Cr. | ₹17,585.00 Cr. | Equity |
| Long-term Borrowings | ₹2,496.00 Cr. | ₹1,604.00 Cr. | ₹1,192.00 Cr. | ₹11,651.00 Cr. | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹3,367.00 Cr. | ₹2,779.00 Cr. | ₹2,682.00 Cr. | ₹18,384.00 Cr. | NoncurrentLiabilities |
| Short-term Borrowings | ₹2,801.00 Cr. | ₹2,334.00 Cr. | ₹1,834.00 Cr. | ₹3,147.00 Cr. | BorrowingsCurrent |
| Trade Payables | ₹1,679.00 Cr. | ₹2,089.00 Cr. | ₹1,820.00 Cr. | ₹2,358.00 Cr. | TradePayablesCurrent |
| Other Current Liabilities | ₹103.00 Cr. | ₹130.00 Cr. | ₹136.00 Cr. | ₹176.00 Cr. | OtherCurrentLiabilities |
| Total Current Liabilities | ₹5,447.00 Cr. | ₹5,426.00 Cr. | ₹4,717.00 Cr. | ₹8,343.00 Cr. | CurrentLiabilities |
| Total Equity and Liabilities | ₹15,012.00 Cr. | ₹15,061.00 Cr. | ₹14,990.00 Cr. | ₹44,312.00 Cr. | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from TORNTPHARM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).